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Whereas the SLAMF-associated protein (SAP) is involved in differentiation of T follicular
helper (Tfh) cells and antibody responses, the precise requirements of SLAMF receptors in
humoral immune responses are incompletely understood. By analyzing mice with targeted
disruptions of the Slamf1, Slamf5, and Slamf6 genes, we found that both T-dependent
and T-independent antibody responses were twofold higher compared to those in sin-
gle knockout mice. These data suggest a suppressive synergy of SLAMF1, SLAMF5, and
SLAMF6 in humoral immunity, which contrasts the decreased antibody responses result-
ing from a defective GC reaction in the absence of the adapter SAP. In adoptive co-transfer
assays, both [Slamf1+5+6]−/− B andT cells were capable of inducing enhanced antibody
responses, but more pronounced enhancement was observed after adoptive transfer of
[Slamf1+5+6]−/− B cells compared to that of [Slamf1+5+6]−/− T cells. In support of
[Slamf1+5+6]−/− B cell intrinsic activity, [Slamf1+5+6]−/− mice also mounted signifi-
cantly higher antibody responses toT-independent type 2 antigen. Furthermore, treatment
of mice with anti-SLAMF6 monoclonal antibody results in severe inhibition of the devel-
opment of Tfh cells and GC B cells, confirming a suppressive effect of SLAMF6. Taken
together, these results establish SLAMF1, SLAMF5, and SLAMF6 as important negative
regulators of humoral immune response, consistent with the notion that SLAM family
receptors have dual functions in immune responses.
Keywords: SLAM family receptors, SLAM-associated protein, follicular T helper cells, germinal center B cells,
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INTRODUCTION
The humoral immune response is crucial for protecting individ-
uals from many infections and eliminating foreign substances.
Antibody responses can be induced in a T cell dependent or T cell
independent manner. In T-independent immunity, the antibody
response occurs directly after B cell activation in T cell deficient
mice. In contrast with T-independent responses, T-dependent
responses require T cell help for B cell activation and maturation.
In the presence of T cell help, B cells undergo robust proliferation
and somatic hypermutation of their variable region genes and dif-
ferentiate into high affinity memory B cells and long-lived plasma
cells in the germinal centers (1, 2). Although several subsets of
CD4+ T helper cells may be implicated in T-dependent humoral
responses, it becomes clear that the follicular helper CD4+ T cell
subset [T follicular helper (Tfh)] is a major B cell help provider
(3–6). Tfh cells exhibit a phenotype distinct from that of other
effector CD4+ T helper cells, as they express the transcription fac-
tor B cell lymphoma 6 (Bcl6) that is necessary for the development
of Tfh cells and inhibits expression of genes critical for develop-
ment of other T helper cells (4, 7–9). Although Bcl6 expression by
pre-Tfh cells is required, it is not sufficient in vivo for full polariza-
tion of Tfh cells. In fact, multiple molecules have been shown to
be involved in the differentiation of Tfh cells (3, 4, 6). In addition,
Tfh development is highly dependent on B cell responses, as Tfh
cells are not found in B cell deficient mice (7, 10, 11). These find-
ings indicate that, through their interaction, GC B cells and Tfh
cells reciprocally provide each other with signaling for survival,
proliferation, and differentiation.
The signaling lymphocytic activation molecule family
(SLAMF) includes nine structurally related Ig-like proteins that are
differentially expressed on the surface of hematopoietic cells (12).
SLAMF receptors have been shown to function as co-stimulatory
molecules and to modulate the activation and differentiation of
a wide array of immune cell types involved in both innate and
adaptive immune responses (12–14). While most SLAMF recep-
tors serve as self-ligands, SLAMF2 and SLAMF4 interact with
each other. Six SLAMF receptors (SLAMF1, SLAMF3, SLAMF4,
SLAMF5, SLAMF6, and SLAMF7) carry one or more copies of
an immunoreceptor tyrosine-based switch motif (ITSM) in their
cytoplasmic tails. This signaling switch motif can recruit SH2
domain-containing signaling molecules such as SLAM-associated
protein (SAP) (15). SAP is a cytoplasmic adapter molecule with
a single Src homology 2 domain and a small carboxy-terminal
region. The SAP family consists of three members: SAP expressing
T, NK, and NKT cells, and EAT-2A and EAT-2B (murine) express-
ing NK cells and APC (12, 16). There is accumulating evidence
that SAP and EAT-2 can function as signaling adaptors that link
SLAMF receptors to active signaling molecules such as the Src
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family protein tyrosine kinases Fyn and PI3K (15, 17–21). SAP
and EAT-2 have also been shown to act as blockers to outcompete
SH2 domain-containing inhibitory molecules SHP1, SHP2, and
SHIP1 (22–28).
Deficiencies in the gene that encodes SAP (SH2D1A) result
in a primary immunodeficiency called X-linked lymphoprolifer-
ative disease (XLP) (29–31). Patients with XLP suffer from fatal
infectious mononucleosis, malignant B cell lymphomas, and dys-
gammaglobulinemia. Defects in humoral responses and lack of
germinal center formation are observed in XLP patients and in
virally infected or immunized SAP-deficient mice (32–36). Con-
siderable evidence indicates that the humoral immune response
defect in XLP patients and SAP−/− mice stems from a defect
in CD4+ helper cells because T-dependent antigen responses are
defective and are restored after reconstitution with WT CD4+
T cells, but not WT B cells (32, 34, 35). However, the role of
SAP in T-dependent humoral responses remains unclear. The
SLAM/SAP/FynT axis regulates IL-4 producing Th2 differenti-
ation, as demonstrated by the observation that Slamf1−/− and
SAP−/− mice have defective Th2 cytokine secretions (37–39). IL-
4 is known to stimulate B cell antibody responses and Ig class
switching, but the R78A mutant SAP mice can mount normal
T-dependent antibody responses even though this mutant SAP
molecule loses Fyn binding motif R78 (40). Recently, Qi and co-
workers elegantly showed that SAP-deficient CD4+ T cells cannot
form lasting mobile conjugate pairs with cognate B cells in the ger-
minal center while the interaction between SAP-deficient T cells
and DC is not affected (41). Since a sustained T-B conjugate allows
their comprehensive activation and subsequent differentiation to
Tfh cells and GC B cells, unstable T-B cell conjugates may con-
tribute to humoral immune deficiency in SAP-deficient mice and
XLP patients.
Compared to severe immunodeficiencies in SAP−/− mice,
single ablation of SLAMF receptors causes a mild phenotype
(40, 42–44). When mice deficient in SLAMF1 (the prototypic
member of the SLAMF receptors) were infected with LCMV,
Tfh cell differentiation, germinal center development, and the
acute or long-term anti-viral antibody responses were comparable
between LCMV-infected WT and Slamf1−/− mice (40). Simi-
lar to Slamf1−/− mice, Slamf3−/−, Slamf5−/−, and Slamf6−/−
mice showed no defects in response to LCMV (28, 42). This
suggests that functional redundancy exists among the SLAMF
receptors, which has been confirmed in NKT cell development in
pseudo Slamf[1+ 6]-deficient bone marrow reconstituting mice
(45) and recent Slamf[1+ 6]−/− mice (46). For more than a
decade, investigating the role of SLAMF receptors in SAP-mediated
signaling has been difficult due to an inability to generate double
or multiple SLAMF receptor deficient mice, as the receptors are
closely located on the same chromosome (12). To define roles of
SLAMF receptors as well as how they interact with one another
in humoral immune responses, we generated Slamf[1+ 6] dou-
ble knockout and Slamf[1+ 5+ 6] triple knockout mice using a
two-time gene targeting technique and Cre/LoxP system. Surpris-
ingly, we found that the combined absence of SLAMF1, SLAMF5,
and SLAMF6 results in higher antibody production in response
to both T-dependent and T-independent antigens. In addition,
the administration of anti-SLAMF6 monoclonal antibody also
impairs humoral immune responses in vivo. These observations
suggest that SLAMF1, SLAMF5, and SLAMF6 function as negative
regulators in T-dependent and T-independent antibody responses.
MATERIALS AND METHODS
MICE
To generate Slamf[1+ 6]−/− and Slamf[1+ 5+ 6]−/− mice, a B6
bacterial artificial chromosome clone (B6 BAC clone #RP23-77A8)
containing the Slamf1 and Slamf6 genes was used to construct a
targeting vector with a neomycin resistant cassette flanked by two
LoxP sites. SLAMF6 ES cell clones heterozygous for the muta-
tion were generated by standard methods. To generate Slamf1 and
Slamf6 double-deficient mice, we used a SLAMF1 targeting vector
to retarget the previously generated SLAMF6 mutant ES cell clone
that was known to give germline transmission with extremely
high frequency. Co-integration of the two targeting vectors on the
same chromosome was assessed by in vitro transfection-targeted
ES cell clones with a Cre recombinase expression vector. Dele-
tion of the whole Slamf1, Slamf5, and Slamf6 locus was confirmed
by PCR (Figures 1A,B). B6 background Slamf5−/− mice have
been reported previously (46). Wild-type C57BL/6 (B6) mice were
obtained from the Jackson Laboratory. Animal studies were con-
ducted in accordance with the National Research Council’s Guide
for the Care and Use of Laboratory Animals and were approved
by the Beth Israel Deaconess Medical Center Institutional Animal
Care and Use Committee.
ANTI-SLAMF RECEPTOR ANTIBODIES
Rat anti-mouse SLAMF1 mAb (9D1) is specific for the extracel-
lular region of mouse SLAMF1 (25). The anti-mouse SLAMF5
mAb was generated by fusing NS1 myeloma cells with spleen cells
obtained from Armenian hamsters, which were immunized three
times with mouse SLAMF5-Fc fusion protein (47). Mouse anti-
mouse SLAMF6 mAbs (13G3 and 330) are specific for the extracel-
lular region of mouse SLAMF6. Anti-SLAMF1, anti-SLAMF5, and
anti-SLAMF6 mAbs used in our studies were purified by affinity
chromatography (Harlan Bioproducts for Science). Anti-SLAMF6
F(ab’)2 fragments were generated from whole SLAMF6 mAb, using
the Thermo Scientific Pierce F(ab’)2 Preparation Kit (PI-44988)
according to manufacturer instructions.
IMMUNIZATION
Mice were immunized intraperitoneally (i.p.) with 40µg of NP-
ovalbumin (NP-OVA, Biosearch Technology) precipitated with
Complete Freund’s Adjuvant (Difco) or Alum. For eliciting TI
antigen responses, mice were i.p. immunized with 20µg of NP28-
Ficoll (Biosearch Technologies) or with 10µg NP-LPS. Mice
were bled on day 9 (for T-dependent antigen) or day 7 (for T-
independent antigen) post-immunization. NP-specific IgG and
IgM titers were determined by ELISA after serial dilutions of the
serum.
ADOPTIVE CELL TRANSFER
Naïve CD4+ and B220+ B cells were purified from the spleens of
WT and Slamf[1+ 5+ 6]−/− mice using a magnetic cell sorting
kit (Miltenyi Biotec). Rag-1−/− recipient mice were injected with
5× 106 CD4+ T cells and 10× 106 B220+ B cells in 200µl PBS.
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FIGURE 1 | Generation of Slamf[1+6]−/− and Slamf[1+5+6]−/− mice.
(A) Schematic representation of the Slamf[1+6] and Slamf[1+5+6]
targeting strategy.Top: illustration of the genomic mouse SLAMF1-5-6 locus
after targeted replacement of exon 2 and 3 of both Slamf1 and Slamf6
genes. Middle: The Slamf1-5-6 locus after Cre-mediated recombination
leading to the deletion of the LoxP site-flanked genomic fragment. Bottom:
PCR genotyping primers (PF and PR) used to confirm the junction of
Cre-mediated deletion from mouse-tail DNA. (B) Thymocytes from WT,
Slamf[1+5]−/−, and Slamf[1+5+6]−/− mice were stained with
anti-SLAMF1, anti-SLAMF5, and anti-SLAMF6 antibodies, and the
expression of SLAMF1, SLAMF5, and SLAMF6 was evaluated by flow
cytometry.
Mice were immunized with NP-OVA/CFA 7 days after adoptive
cell transfer.
ELISA
Serum was collected from mice on day 7 or 9. High binding
plates (Costar) were coated overnight at 4°C with [NP(4)-BSA] or
[NP(25)-BSA] (50µg/ml, Biosearch Technologies). Horseradish
peroxidase-conjugated sheep anti-mouse IgG antibody (Amer-
sham) was used for detection. Relative affinity of the NP-specific
IgG antibodies was calculated from the ratio of antibody binding
to low-density hapten [NP(4)-BSA] versus high-density hapten
[NP(25)-BSA] coated plates.
FLOW CYTOMETRY
Single-cell suspensions of splenocytes, thymocytes, and inguinal
lymph nodes were stained with the following antibodies and
reagents after blocking non-specific binding with CD16/32 and
15% rabbit-serum: αCD4 (RM4-5), αPD-1 (RMP1-30), αCD44
(IM7),αCD138 (281-2),αB220 (RA3-6B2),αFas (Jo2),αT- and B-
cell activation antigen (GL-7), and αIgD (11-26) purchased from
eBioscience, BD Pharmingen, or Biolegend. NP32-phycoerythrin
was purchased from Biosearch Technologies (N-5070-1). For
staining of CXCR5, biotinylated-αCXCR5 (2G8, BD Biosciences)
was used, followed by PE-labeled streptavidin (eBioscience).
For staining of NP-PE, splenocytes were fixed for 10 min with
4% paraformaldehyde, then were washed with flow cytometry
buffer with 0.2% saponin, and stained in the presence of 0.2%
saponin. Data were acquired using an LSRII flow cytometer (BD
Pharmingen) and analyzed using FlowJo software, Version 8.8.6
(TreeStar Inc.).
STATISTICAL ANALYSIS
Statistical significance was determined by unpaired t -test (two-
tailed with equal SD) using Prism software (GraphPad, San
Diego, CA, USA). The p-value <0.05 was considered statistically
significant.
RESULTS
GENERATION OF Slamf[1+ 6]−/− AND Slamf[1+ 5+ 6]−/− MICE
Since the murine SLAMF1, SLAMF5, and SLAMF6 genes are
closely linked on mouse chromosome 1, a mouse strain lacking
Slamf[1+ 6] or Slamf[1+ 5+ 6] cannot be generated by inter-
breeding individual Slamf1−/−, Slamf5−/−, and Slamf6−/−mice.
To generate Slamf[1+ 6]−/− and Slamf[1+ 5+ 6]−/− mice, we
first replaced exons 2 and 3 of the Slamf6 gene with a LoxP-
flanked PGK-NeoR cassette in the first targeting event in B6 ES
cells (Figure 1A). We next transfected one of the SLAMF6-targeted
ES cell clones with a vector that replaced exons 2 and 3 of the
Slamf1 gene with a hygromycin resistant gene containing a LoxP
site, thus generating Slamf[1+ 6] −/+ ES cells. To identify ES cell
clones in which both insertions had taken place on the same chro-
mosome, we removed the LoxP-flanked chromosome fragment
of 200 Kb, which includes the Slamf1, Slamf5, and Slamf6 genes.
The confirmed Slamf[1+ 6]−/+ ES cell clones were used to gen-
erate Slamf[1+ 6]−/− mice. Subsequently, Slamf[1+ 6]−/− mice
were bred to CreTg mice to obtain Slamf[1+ 5+ 6]−/− mice
(Figure 1A). The absence of Slamf[1+ 6] and Slamf[1+ 5+ 6]
expression was confirmed by flow cytometric analyses using
SLAMF1, SLAMF5, and SLAMF6 specific antibodies (Figure 1B).
THE NUMBER OF MARGINAL ZONE B CELLS IS SIGNIFICANTLY
INCREASED IN Slamf[1+ 5+ 6]−/− MICE
Thymic development and the number of splenic T cells were
not altered in Slamf[1+ 6]−/− or Slamf[1+ 5+ 6]−/− mice
(Figures S1A,C in Supplementary Material). However, a close
examination of the B cell compartment by flow cytometric analysis
revealed that the number and percentage of marginal zone (MZ)
B cells (sIgMhiAA4.1-CD19+CD21hiCD23lo-neg) was signifi-
cantly increased in Slamf[1+ 5+ 6]−/− mice as compared to WT
and Slamf[1+ 6]−/− mice (Figures 2A–C). By contrast, the per-
centage and number of T and B cells and the number of splenocytes
in Slamf[1+ 5+ 6]−/− mice were identical to those in WT mice
(Figure 2D; Figures S1A–C in Supplementary Material). The pop-
ulation of follicular B cells (AA4.1−CD21+CD23+sIgMint) in the
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FIGURE 2 | Comparison of B cell andT cell populations in
Slamf[1+5]−/−, Slamf[1+5+6]−/−, and WT mice. Flow cytometric
analyses of B cell and T cell subsets in the spleens of Slamf[1+ 6]−/−,
Slamf[1+5+ 6]−/−, and WT mice: (A) CD19+AA4-IgMhi cells in spleens are
gated for the expression of CD23 and CD21 to delineate CD21+CD23-
marginal zone (MZ) B cells. (B) Percentage of CD19+AA4−IgMhiCD21+
CD23− MZ B cells. (C) The number of CD19+AA4−IgMhi CD21+CD23- MZ
B cells. (D) Splenocytes from Slamf[1+6]−/−, Slamf[1+5+6]−/−, and WT
mice are stained for surface expression of CD3 and CD19. (E) CD19+
AA4−IgMhiCD21 cells in spleens are gated for the expression of CD23 and
CD21 to delineate CD21+CD23+ follicular B cells in the spleens.
(F) Transitional B cell subsets in spleens are stained for the expression
of CD19, AA4.1, CD23, and IgM: T1 (CD19+AA4+IgMhiCD23-), T2
(CD19+AA4+IgMhiCD23+), and T3 (CD19+AA4+IgMloCD23-).
spleens of Slamf[1+ 6]−/− and Slamf[1+ 5+ 6]−/− mice was
similar to that in WT mice (Figure 2E). Similarly, the frequen-
cies of CD5+ B1a and CD5− B1b cells were comparable in the
peritoneal cavity of mutant and WT mice (Data not shown).
Immature peripheral B cells can be divided into three transitional
populations based on their surface marker expression, designated
as transitional type 1 (T1) (AA4.1+sIgMintCD23-), transitional
type 2 (T2) (AA4.1+sIgMhiCD23-), and transitional type 3 (T3)
(AA4.1+sIgMintCD23+). Similarly, the frequencies of T1, T2,
and T3 immature B cell populations in Slamf[1+ 6]−/− and
Slamf[1+ 5+ 6]−/− mice were not significantly different from
those of wild-type mice (Figure 2F). Collectively, these find-
ings show that the ablation of SLAMF1, SLAMF5, and SLAMF6
affects the development of MZ B cells, but other B cell subsets
and T cell development occur normally in Slamf[1+ 6]−/− and
Slamf[1+ 5+ 6]−/− mice.
ENHANCED T CELL DEPENDENT ANTIBODY PRODUCTION IN
Slamf[1+ 5+ 6]−/− MICE
Although most SLAMF receptors are expressed on the surface
of T and B cells, ablation of single SLAMF genes does not lead
to significant defects in germinal center formation after protein
immunization or viral infection (27, 42, 44). In contrast, the
absence of SAP, the SLAMF specific adaptor, leads to a severe defect
in humoral response (14, 32, 34), which suggests functional redun-
dancies in the control of antibody responses by SLAMF receptors.
To test this hypothesis, we compared NP-specific antibody pro-
duction by Slamf[1+ 6]−/−, Slamf[1+ 5+ 6]−/−, and WT mice.
Slamf[1+ 6]−/− mice, which had been immunized with NP-OVA
in CFA, produced similar amounts of NP-specific serum IgM as
WT mice (data not shown). However, the level of anti-NP IgG
in the serum of Slamf[1+ 6]−/− mice was consistently higher,
although statistical analysis did not reach significance (Figure 3A).
Surprisingly, the additional disruption of the Slamf5 gene signifi-
cantly augmented the level of anti-NP IgG in Slamf[1+ 5+ 6]−/−
mice (Figure 3A) even though NP-specific IgM production was
not altered (data not shown). Affinity maturation of NP-specific
IgG was comparable between the mutant and WT mice (data
not shown). Because Slamf[1+ 5+ 6]−/− mice produced higher
NP-specific IgG compared to Slamf[1+ 6]−/− mice, we reasoned
that SLAMF5 signaling might suppress antibody responses. To
test this, we then immunized Slamf5−/− mice with NP-OVA.
In contrast to a previous report (41), Slamf5 deficiency had no
effect on NP-specific antibody production or the development
of Tfh cells or GC B cells (Figures 3B–F). Taken together, the
data support the notion that SLAMF1, SLAMF5, and SLAMF6
cooperate in the negative regulation of T-dependent antibody
responses.
THE COMBINED ABSENCE OF SLAMF1, SLAMF5, AND SLAMF6
ENHANCES ANTIGEN SPECIFIC PLASMA CELL EXPANSION, BUT HAS
NO EFFECT ON THE DEVELOPMENT OF GC B CELLS, TFH CELLS, OR T
FOLLICULAR REGULATORY (TFR) CELLS
As strong humoral immune responses, characterized by GC for-
mation and long-lived plasma and memory B cells, are dependent
on help provided by CD4+ Tfh cells (4, 5, 48), we next exam-
ined whether enhanced T-cell dependent antibody responses in
Slamf[1+ 5+ 6]−/− mice are correlated with an increase in Tfh
cell differentiation and higher germinal center responses after
immunization with NP-OVA. Contrary to our prediction, the
percentage and number of Tfh cells was comparable between
Slamf[1+ 5+ 6]−/− and WT mice (Figure 3C; Figure S2A in
Supplementary Material). Percentages of GC B cells (FAS+ GL-
7+) were also unaffected by the combined absence of SLAMF1,
SLAMF5, and SLAMF6 (Figure 3E; Figure S2B in Supplementary
Material).
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FIGURE 3 | A combination of SLAMF1, SLAMF5, and SLAMF6
negatively regulatesT cell dependent antibody responses, but normal
Tfh and GCB development is observed in Slamf[1+5+ 6]−/− mice. WT,
Slamf5−/−, Slamf[1+6]−/−, and Slamf[1+5+6]−/− mice were immunized
with 40µg of NP-OVA and serum was collected on day 9. (A) NP-specific
IgG titers for Slamf[1+6]−/−, Slamf[1+5+6]−/−, and WT mice immunized
with NP-OVA in CFA were determined by ELISA using NP(4)-BSA coated
plates. (B) NP-specific IgG titers for Slamf5−/−, Slamf[1+6]−/−,and WT
mice immunized with NP-OVA in Alum were determined by ELISA using
NP(4)-BSA coated plates. (C) Percentage of Tfh cells (CD4+PD-1+CXCR5+)
in the spleens of Slamf[1+6]−/−, Slamf[1+5+6]−/−, and WT mice.
(D) Percentage of Tfh cells (CD4+PD-1+CXCR5+) in the spleens of
Slamf5−/−, Slamf[1+6]−/−, and WT mice. (E) Percentage of Germinal
Center B cells (B220+GL7+Fas+) in the spleens of Slamf[1+6]−/−,
Slamf[1+5+6]−/−, and WT mice. (F) Percentage of Germinal Center B
cells (B220+GL7+Fas+) in the spleens of Slamf5−/−, Slamf[1+6]−/−, and
WT mice. Data represent at least three independent experiments.
Given the increased antibody responses observed in
Slamf[1+ 5+ 6]−/− mice, we hypothesized that the absence of
SLAMF, SLAMF5, and SLAMF6 may enhance either plasma cell
differentiation or their capacity to produce antibody. To test
this hypothesis, we evaluated NP-specific plasma cells in NP-
OVA immunized mice. Consistent with high antibody responses,
the frequency of plasma cells (B220+IgD-CD138+) was signif-
icantly increased in Slamf[1+ 5+ 6]−/− mice (Figures 4A,B).
Furthermore, flow cytometric analysis confirmed an increase in
NP-specific plasma cells in immunized Slamf[1+ 5+ 6]−/− mice
as compared to wild-type mice (Figures 4C,D). Together, the data
indicate that the absence of SLAMF1, SLAMF5, and SLAMF6 has
no effect on Tfh and GC B cell development, but that it appears to
regulate development of antigen specific plasma cells.
A new Treg cell subset termed Tfr cells has recently been iden-
tified (49, 50). These cells, which express not only CXCR5 and
PD-1 but also the transcription factors Bcl6 and FoxP3, suppress
both Tfh cells and GC B cells. As Tfr cell differentiation requires
SAP expression (49), it is possible that the absence of SLAMF1,
SLAMF5, and SLAMF6 might also cause a defect in Tfr cell devel-
opment, thereby contributing to the enhanced antibody responses
in Slamf[1+ 5+ 6]−/− mice. To assess the impact of the com-
bined absence of SLAMF1, SLAMF5, and SLAMF6 on Tfr cell dif-
ferentiation, we immunized mice with NP-OVA and analyzed Tfr
cells 7 days later. The frequency of Tfr cells (CD4+CXCR5highPD-
1highFoxP3+) was not significantly affected in Slamf[1+ 6]−/−
or Slamf[1+ 5+ 6]−/−mice (Figure S3A in Supplementary Mate-
rial). Although the expression of Ki67, a marker used to identify
proliferating cells, is slightly decreased in Slamf[1+ 5+ 6]−/− Tfr
cells, it is not statistically significant (Figure S3B in Supplemen-
tary Material). Thus, while the enhanced antibody production
may not result from a defect in Tfr differentiation, its func-
tional inability would not be excluded in Slamf[1+ 5+ 6]−/−
mice.
SLAMF[1+ 5+ 6]−/− B OR T CELLS ADOPTIVELY TRANSFERRED TO
RAG-1 DEFICIENT MICE CAN INDUCE ENHANCED ANTIBODY
RESPONSES
As SLAMF1, SLAMF5, and SLAMF6 are expressed on both B
cells and T cells, it was not clear on which cell type ablation of
their expression was critical for the altered T-dependent antibody
responses observed in Slamf[1+ 5+ 6]−/− mice. This prompted
us to evaluate potential contributions of Slamf[1+ 5+ 6]−/− T
and B cells to the enhanced humoral responses by using the adop-
tive transfer of naïve T and B cells. To this end, four combinations
of CD4+ cells and B cells were transferred into Rag-1−/− recip-
ient mice: WT CD4+ T and WT B cells, Slamf[1+ 5+ 6]−/−
CD4+ T and Slamf[1+ 5+ 6]−/− B cells, WT CD4+ T and
Slamf[1+ 5+ 6]−/− B cells, and Slamf[1+ 5+ 6]−/− CD4+
T and WT B cells. Seven days post-transfer, the recipient
Rag-1−/− mice were immunized with NP-OVA in CFA. Rag-
1−/− mice reconstituted with CD4+ T cells and B cells from
Slamf[1+ 5+ 6]−/− mice had significantly higher NP-specific
antibody production than recipient mice that had been recon-
stituted with WT CD4+ T cells and B cells (Figure 5). Interest-
ingly, the transfer of Slamf[1+ 5+ 6]−/− B cells together with
WT CD4+ T cells was sufficient to induce a stronger antibody
response as compared to the transfer of WT CD4+ T cells and B
cells. Although the transfer of Slamf[1+ 5+ 6]−/− CD4+ T cells
and WT B cells also led to increased titers of NP-specific IgG,
the magnitude of the antibody responses was less pronounced
(Figure 5). Thus, we concluded that Slamf[1+ 5+ 6]−/− T and
B cells both have intrinsic activity, but that the enhanced T-
dependent humoral response in Slamf[1+ 5+ 6]−/− mice mainly
results from Slamf[1+ 5+ 6]−/− B cells.
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FIGURE 4 | A combined absence of SLAMF1, SLAMF5, and
SLAMF6 enhances antigen specific plasma cell expansion.
Slamf[1+6]−/−, Slamf[1+5+6]−/−, and WT mice were immunized
with NP-OVA in CFA. After 9 days, spleens were isolated and subjected
to staining with the indicated antibodies and analyzed by flow
cytometry. (A) Representative FACS plots showing B220+IgD-CD138+
plasma cells from the spleens of Slamf[1+6]−/−, Slamf[1+5+6]−/−,
and WT mice. (B) Percentage of Plasma cells (B220+IgD-CD138+) from
the spleens of Slamf[1+6]−/−, Slamf[1+5+6]−/−, and WT mice.
(C) Representative FACS plots showing B220+NP+IgD- NP-specific
plasma cells from the spleens of Slamf[1+5+6]−/− and WT mice.
(D) Percentage of NP-staining plasma cells (B220+NP+IgD-) from the
spleens of Slamf[1+5+6]−/− and WT mice. Data represent at least
three independent experiments.
ENHANCED T-INDEPENDENT ANTIBODY RESPONSES ARE OBSERVED
IN Slamf[1+ 5+ 6]−/− MICE
Because Slamf[1+ 5+ 6]−/− mice have a high frequency of MZ
B cells (Figures 2A,B) that are known to participate in responses
to T-independent antigens, we questioned whether T-independent
antibody responses are affected in Slamf[1+ 5+ 6]−/−mice. Con-
sequently, we examined the SLAMF mutant mice in response to
NP-Ficoll, a classical synthetic TI-2 antigen that induces murine
Ag-specific B cells to expand, differentiate, and produce NP-
specific antibodies. As anticipated, the serum concentrations of
NP-specific IgM and IgG3 in Slamf[1+ 5+ 6]−/− mice were
increased on day 7 after immunization compared to those in WT
mice (Figures 6A,B). In contrast, NP-specific IgM and IgG3 titers
were comparable in WT and Slamf[1+ 6]−/−mice (Figures 6A,B).
As responses to NP-LPS were not altered (data not shown), the
enhanced TI-2 responses are specifically linked to the combined
absence of SLAMF1, SLAMF5, and SLAMF6.
ANTI-SLAMF6 ANTIBODY INHIBITS HUMORAL IMMUNE RESPONSES
The observation that the ablation of SLAMF1, SLAMF5, and
SLAMF6 enhances T-dependent and T-independent antibody
responses suggests that they function as potential inhibitory mol-
ecules in humoral immune responses. In addition, a recent report
indicates that SLAMF6 transmits inhibitory signaling in Tfh dif-
ferentiation and NKT development in the context of the absence
of SAP (27). To directly evaluate whether triggering of a single
SLAMF receptor would initiate inhibitory signaling in humoral
responses, we first sought to trigger SLAMF6 by using anti-
SLAMF6 mAb in NP-OVA-immunized mice. As shown in Figure 7,
the treatment of WT mice with anti-SLAMF6 (330) dramatically
impaired NP-specific IgG production 9 days post-immunization
of NP-OVA (Figure 7A). As negative control, anti-SLAMF6 had
no detectable effects on antibody production in Slamf[1+ 6]−/−
mice (Figure S4A in Supplementary Material). Noticeably, anti-
SLAMF6 injected mice had a significant reduction in IgG high
affinity antibody (Figure 7B). Furthermore, NP-specific IgM pro-
duction and its affinity maturation also were impaired in anti-
SLAMF6 injected mice (Figures 7C,D). In correlation with the
impaired antibody response, the frequencies and absolute num-
bers of splenic GC B cells (GL7+Fas+) (Figures 8A–C) and Tfh T
cells (CXCR5+PD-1+) (Figures 9A–C) were significantly reduced
in anti-SLAMF6 injected mice. A reduced number of plasma cells
was also observed in anti-SLAMF6 injected mice (Figures 8D,E),
but effector B cell and T cell populations were equivalent in
anti-SLAMF6 injected and non-injected mice (Figure 8F and
Figures 9D,E). In order to confirm the inhibitory effects of
anti-SLAMF6 (330), another anti-SLAMF6 mAb (13G3) was
also tested. As expected, a similar inhibitory effect was seen in
13G3-injected mice (Figures S4A,B in Supplementary Material).
To address whether the administration of anti-SLAMF6 affects
early commitment to antigen specific Tfh cells and GC B cells or
late stages of humoral responses, immunized mice were injected
with anti-SLAMF6 four days post-immunization, at which point T
and B cells are already committed to becoming Tfh and GC B cells
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FIGURE 5 |The adoptive transfer of naïve Slamf[1+5+6]−/− T or B cells
enhanced NP-specific antibody responses after co-transfer of WT B or
T cells into Rag-1−/− mice. CD4+ T cells (5×106) together with 10×106
B cells are isolated from WT and Slamf[1+5+6]−/− mice and transferred
into Rag-1−/− recipients in the following four combinations of T and B cells:
WT CD4+ T and WT B cells, Slamf[1+5+6]−/− CD4+ T and Slamf[1+5+
6]−/− B cells, WT CD4+ T and Slamf[1+5+6]−/− B cells, and Slamf[1+5+
6]−/− CD4+ T and WT B cells. The Rag-1−/− recipients were immunized with
40µg of NP-OVA in CFA 7 days after the transfer. Mice were sacrificed and
NP-specific IgG titers were determined by ELISA day 9 post-immunization.
Data are representative of three independent experiments.
FIGURE 6 | A combined ablation of SLAMF1, SLAMF5, and SLAMF6
shows a selective increase in MZ B cells and enhancedTI-2 antibody
responses. WT, Slamf[1+6]−/−, and Slamf[1+5+6]−/− mice were
immunized with 20µg of NP-Ficoll. NP-specific IgM (A) and IgG3 (B) titers
were determined at day 7 by ELISA after serial dilutions of the serum.
Results are representative of three independent experiments.
(51). Interestingly, the late injection of mice with anti-SLAMF6
did not significantly reduce GC response and antibody produc-
tion (data not shown). This suggests that the signal initiated by
SLAMF6 has efficient inhibition in early Tfh and GC B cell differ-
entiations, but has little effect on late Tfh and GC B cell expansion
and antibody production.
FIGURE 7 | Administration of anti-SLAMF6 antibody has a negative
effect on antibody production in protein-immunized WT mice. Mice
were immunized with 40µg NP-OVA in CFA and some were injected with
either 250µg of anti-SLAMF6 (330), anti-SLAMF1 (9D1), anti-SLAMF5 (M5),
or mouse Ig isotype control. The mice were sacrificed on day 9 and serum
was collected to measure Ig production. (A) NP-specific IgG titers from
sera of anti-SLAMF6 injected mice were determined by ELISA. (B) Affinity
of NP-specific IgG in immune-sera collected as in (A). (C) NP-specific IgM
titers from sera of anti-SLAMF6 injected mice were determined by ELISA.
(D) Affinity of NP-specific IgM in immune-sera collected as in (C).
(E) NP-specific IgG titers from sera of anti-SLAMF1 injected mice were
determined by ELISA. (F) NP-specific IgG titers from sera of anti-SLAMF5
injected or non-injected immunized mice were determined by ELISA.
Results are representative of three independent experiments.
To evaluate whether the Fc portion of anti-SLAMF6 influ-
ences immune function, anti-SLAMF6 F(ab’)2 fragments were
injected into mice along with NP-OVA immunization. Similar
to intact anti-SLAMF6, anti-SLAMF6 F(ab’)2 caused a signif-
icant decrease in the percentage and number of GC B cells
(Figures 10B,C) and Tfh cells (Figures 10D,E). In contrast, an
impaired NP-specific antibody production was not observed in
the anti-SLAMF6 F(ab’)2 injected mice. To exclude the possibil-
ity that NK cells mediate natural cytotoxicity against a variety
of immune cells, we examined splenocyte phenotype and levels of
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FIGURE 8 | Administration of anti-SLAMF6 (330) antibody has a negative
effect on GC B cell differentiation in protein-immunized WT mice. Mice
were immunized with 40µg of NP-OVA in CFA and some mice were injected
with either 250µg anti-SLAMF6 (330) or Ig isotype control. The mice were
sacrificed on day 9. (A) Representative flow cytometry staining of
B220+GL7+Fas+ Germinal Center B cells in the spleens of anti-SLAMF6,
isotype, and non-injected immunized mice. (B) Percentage of Germinal
Center B cells (B220+GL7+Fas+) in the spleens of anti-SLAMF6, isotype, and
non-injected immunized mice was determined by flow cytometry. (C) The
numbers of Germinal Center B cells (B220+GL7+Fas+) in the spleens of
anti-SLAMF6, isotype, and non-injected immunized mice were determined by
flow cytometry. (D) Representative of flow cytometry staining of
B220+IgD-CD138+ plasma cells in the spleens of anti-SLAMF6, isotype, and
non-injected immunized mice. (E) Percentage of plasma cells
(B220+IgD-CD138+) in the spleens of anti-SLAMF6, isotype, and non-injected
immunized mice. (F) Percentage of B220+CD86+ activated B cells in the
spleens of anti-SLAMF6, isotype, and non-injected immunized mice. Results
are representative of three independent experiments.
NP-specific antibody in NK-depleted WT mice following NP-OVA
immunization and anti-SLAMF6 injection. Notably, the depletion
of NK cells did not impact the capacity of anti-SLAMF6 to sup-
press antibody production or the development of Tfh cells and
GC B cells (data not shown). Thus, severely impaired antibody
production by the injection of anti-SLAMF6 is not due to NK
cell-mediated ADCC.
Based on the studies using anti-SLAMF6, we next examined the
ability of anti-SLAMF1 mAb and anti-SLAMF5 mAb to suppress
humoral immune responses in NP-OVA immunized mice. We
found that NP-specific antibody production was moderately, but
consistently, reduced in anti-SLAMF1 injected mice (Figure 7E).
However, anti-SLAMF5 did not suppress antibody production
(Figure 7F). In addition, the frequencies of GC B cells and Tfh cells
were comparable among the non-injected,anti-SLAMF1,and anti-
SLAMF5 injected mice (data not shown). Thus, the results suggest
that neither anti-SLAMF1 nor anti-SLAMF5 is alone sufficient to
have a significant impact on humoral responses.
DISCUSSION
An important role of SAP in T cell help to B cells has been
highlighted in defects in follicular T helper cell differentiation
and lack of germinal center development in XLP patients and
in virally infected or immunized SAP−/− mice (4, 12, 13, 32, 48,
52). Although SAP has been proven to bind to ITSMs in most
SLAMF receptors upon ligand stimulation, how these receptors
function in the presence and absence of SAP is poorly under-
stood, particularly in B cells. In this study, we provide in vivo
evidence that SLAMF1, SLAMF5, and SLAMF6 synergistically
suppress T-dependent and T-independent antibody responses,
as Slamf[1+ 5+ 6]−/− mice, but not Slamf[1+ 6]−/− mice or
single SLAMF mutant mice, exhibit a significant enhancement
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FIGURE 9 | Administration of anti-SLAMF6 (330) antibody has a
negative effect onTfh cell differentiation in protein-immunized WT
mice. Mice were immunized with 40µg of NP-OVA in CFA and some mice
were injected with either 250µg anti-SLAMF6 (330) or Ig isotype control.
The mice were sacrificed on day 9. (A) Representative flow cytometry
staining of CD4+PD-1+CXCR5+ Tfh cells in the spleens of anti-SLAMF6,
isotype, and non-injected immunized mice. (B) Percentage of Tfh cells
(CD4+PD-1+CXCR5+) was determined by flow cytometry in the spleens of
anti-SLAMF6, isotype, and non-injected immunized mice. (C) The number
of Tfh cells (CD4+PD-1+CXCR5+) was determined by flow cytometry in the
spleens of anti-SLAMF6, isotype, and non-injected immunized mice.
(D) Percentage of CD4+CD44hiCD62lo memory T cells in the spleens of
anti-SLAMF6, isotype, and non-injected immunized mice. (E) Percentage of
CD4+CD44hiCD69hi activated T cells in the spleens of anti-SLAMF6,
isotype, and non-injected immunized mice. Results are representative of
three independent experiments.
of antibody production. Strikingly, an adoptive transfer assay
shows that the enhanced antibody responses depend largely on
Slamf[1+ 5+ 6]−/− B cells, which indicates that the absence of
SLAMF1, SLAMF5, and SLAMF6 induces intrinsic B cell activity.
Furthermore, injection of mice with anti-SLAMF6 mAb dramat-
ically reduced antibody responses accompanied by impairing Tfh
cell and GC B cell development in spite of a less suppressive effect of
anti-SLAMF1 mAb on antibody responses. Our results therefore
point to a new and important mechanism by which SLAMF1,
SLAMF5, and SLAMF6 regulate humoral responses in B cells.
FIGURE 10 | Administration of anti-SLAMF6 (330) F(ab’)2 antibody has
a similar negative effect on GC B cell andTfh cell development in
protein-immunized WT mice. Mice were immunized with 40µg of
NP-OVA in CFA and some were injected with 250µg of anti-SLAMF6 F(ab’)2
on day 0 and day 4. The mice were sacrificed on day 9 and serum was
collected to measure IgG production. (A) NP-specific IgG titers were
determined by ELISA. (B–C) The percentage and number of Germinal
Center B cells (B220+GL7+Fas+) were determined by flow cytometry.
(D–E) The percentage and number of Tfh cells (CD4+PD-1+CXCR5+) were
determined by flow cytometry. Results are representative of three
independent experiments.
Maintaining sustained CD4+ T cell adhesion to B cells is
required for Tfh differentiation and germinal center development,
which allows for important signal transfer between T and B cells.
SAP-deficient T cells fail to form a stable T-B cell conjugate (41)
and thereby severely impaired development of Tfh cells and GC B
cells becomes a hallmark in XLP patients and SAP−/−mice (14, 32,
34, 41). Although most SAP-binding SLAMF receptors are highly
expressed on resting and activated T and B cells and implicate a
diverse array of lymphocyte functions, including sustained T-B
cell conjugates (43, 53), the deficiencies in single SLAMF receptors
actually exhibit mild phenotypes. However, in contrast to our cur-
rent study, Slamf5−/− mice have previously been shown to have a
defect in germinal center development and T-dependent antibody
production in protein immunization (43). The reason that the
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same B6 background Slamf5−/− mice strains have different phe-
notypes is not clear. One explanation for this discrepancy is that the
presence of selection marker (Neo) could influence neighboring
genes in targeted loci (54). Alternatively, it remains possible that
the discordant findings could reflect the different environmental
conditions of animal facilities.
Because the functional redundancies in SLAMF-mediated sig-
naling have been demonstrated in NKT cell development (45, 46),
we speculate that multiple deficiencies in SLAMF receptors may
have a strong influence on humoral immune responses that are
able to recapitulate most of the phenotypic alterations observed
in SAP−/− mice. Surprisingly, in our in vivo studies comparing
T-dependent antibody responses, loss of expression of SLAMF1,
SLAMF5, and SLAMF6 receptors actually removed inhibitory sig-
naling and resulted in higher antibody responses (Figure 3A).
When the antibody responses in mice lacking Slamf[1+ 6] were
compared to those in WT mice, there was also a consistent increase
in NP-specific antibody titer, but the effect was less pronounced
than that observed in the combined ablation of SLAMF1, SLAMF5,
and SLAMF6. Although some variability in antibody responses
between mutant and WT mice occurs, statistical analysis always
reached significance. These findings indicate that the homophilic
binding of SLAMF1, SLAMF5, and SLAMF6 synergistically trans-
mits inhibitory signaling during humoral immune responses. The
dual function of SLAMF receptors was initially reported in NK
cell studies. In human NK cells, SLAMF4 predominantly func-
tions as an activating receptor because engagement of SLAMF4
with SLAMF2 mediates NK cell cytotoxicity, cell proliferation,
and cytokine secretion. However, in NK cells from XLP patients,
the SLAMF2–SLAMF4 interaction fails to activate NK cells, but
rather inhibits NK-medicated cytolysis (23). Besides SLAMF4,
other SLAMF receptors such as SLAMF3, SLAMF5, and SLAMF6
become inhibitory molecules instead of activating receptors in
mouse NK cells lacking SAP, EAT-2A, and EAT-2B (55). Consis-
tent with these findings, a similar inhibitory effect of SLAMF6 on
humoral responses and NKT cell development was reported in the
context of the absence of SAP (27). Collectively, these observations
suggest that most SLAMF receptors can mediate either positive
or negative signaling, depending on the expression of SLAMF
adaptors, SAP and EAT-2. Given that SAP and EAT-2A/B are
not expressed in B cells, the homophilic interactions of SLAMF1,
SLAMF5, and SLAMF6 between T and B cells or B and B cells
would result in preferential binding to inhibitory signaling mol-
ecules (e.g., SHP1) in B cells because of the lack of competition
of SAP and EAT-2 for ITSMs of SLAMF receptors. This idea is
supported by our adoptive transfer assays, in which B cells from
Slamf[1+ 5+ 6]−/− mice led to a further enhancement in anti-
body responses compared to the transfer of Slamf[1+ 5+ 6]−/− T
cells. Furthermore, Slamf[1+ 5+ 6]−/− mice display higher anti-
body responses in the absence of T cell help when immunized with
T-independent antigen NP-Ficoll, which directly indicates that an
intrinsic B cell hyperactivation exists in Slamf[1+ 5+ 6]−/−mice.
Although the higher antigen specific antibody production does
not accompany enhanced Tfh and GC B cell responses in the
absence of SLAMF1, SLAMF5, and SLAMF6, increased develop-
ment of plasma cells is consistently observed in NP-OVA immu-
nized Slamf[1+ 5+ 6]−/− mice (Figures 4A–D). The mechanism
regulating plasma cell differentiation is only partly understood.
Two transcription factors Bcl-6 and Blimp-1 reciprocally modu-
late differentiation of GC B cells and plasma cells (52). Cytokines
and chemokines also provide crucial survival signals to plasma cells
(56). Far less is known about SLAMF receptor-mediated signals for
plasma cell differentiation and function. However, in our exper-
iments, we provide interesting evidence that SLAMF1, SLAMF5,
and SLAMF6 negatively regulate either plasma cell differentia-
tion and/or expansion in humoral immune responses. Further
work will assess how SLAMF receptors are involved in plasma cell
development at a molecular level.
The interesting finding in this study is that Slamf[1+ 5+ 6]−/−
mice exhibit an increased frequency of MZ B cells. A cell-fate deci-
sion between follicular B cells and MZ B cells occurs in the transi-
tional (T2) B cell stage, when T2 B cells differentiate into follicular
B cells or MZ B cells after integration of BCR signal strength and
signaling via other essential signaling molecules (57–59). Like in
GC B cells, SLAMF1, SLAMF5, and SLAMF6 are highly expressed
in transitional B cells and MZ B cells (ImmGen.org), and therefore,
signaling resulting from their homophilic interaction may impli-
cate differentiation, migration, or survival of MZ B cells. Since
differentiation of transitional B cells was not altered in Slamf[1+
5+ 6]−/− mice, signaling initiated by SLAMF1, SLAMF5, and
SLAMF6 seems to play a critical role in controlling the develop-
ment and/or survival of MZ B cells. It has been described that MZ
B cells and B1 cells are prime B cell subpopulations responding to
T-independent antigens (60, 61). Interestingly, in spite of increased
pools of MZ B cells, Slamf[1+ 5+ 6]−/− mice showed enhanced
immune responses to the TI-2 Ag NP-Ficoll, but not to the TI-1
Ag NP-LPS. The fact that enhanced TI-antigen response is only
limited to TI-2 antigens suggests that Slamf[1+ 5+ 6]−/− MZ B
cell intrinsic activity, not number, seems to be more critical in
determining the extent of humoral immunity. Thus, these results
provide evidence that synergistic activity of SLAMF1, SLAMF5,
and SLAMF6 may be implicated in functional activity of MZ B
cells.
Complementary approaches with SLAMF receptor-deficient
mice and SLAMF-specific antibodies are important for under-
standing the functions of their immunoregulatory pathways.
Recently, SLAMF6 was found not only to constitutively associate
with SHP1 in SAP-sufficient cells, but also to co-distribute with
the CD3 complex. The ligation of SLAMF6 can reduce CD3ζ
phosphorylation (53). Based on these findings, we hypothesize
that crosslinking of SLAMF6 by anti-SLAMF6 mAb may cause
high phosphorylation in its ITSM. Subsequently, protein tyrosine
phosphatases and lipid phosphatases are preferentially recruited to
SLAMF6, particularly in SAP and EAT-2 negative B cells. Surpris-
ingly, we found that treatment of WT mice with anti-SLAMF6
almost recapitulates the phenotype observed in SAP−/− mice,
which showed a marked defect in Tfh cell and GC B cell forma-
tion and reduced antibody production and affinity maturation.
Interestingly, a significant defect in humoral response was not
observed when mice were treated with anti-SLAMF6 four days
after antigen exposure. This further indicates that SLAMF6-
mediated inhibitory signals have distinct roles in the early differen-
tiation of Tfh cells and GC B cells. However, the administration of
anti-SLAMF6 F(ab’)2 fragments did not fully suppress NP-specific
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FIGURE 11 | A model of SLAMF receptors: SHP1/2 action on the BCR
during B cell activation. When B cells are activated, the ITSMs of
SLAMF1, SLAMF5, and SLAMF6 recruit SHP1/2 and translocate these
phosphatases to the vicinity of the B cell antigen receptor. Signaling from
the BCR is thus down-regulated, maintaining proper response to antigens
in humoral responses. When SLAMF1, SLAMF5, and SLAMF6 are deleted
from B cells, inhibitory signaling mediated by SLAMF and SHP1/2 is
dampened, which induces enhanced humoral responses.
antibody production even though the development of Tfh cells
and GC B cells was significantly impaired (Figure 10). This dif-
ference may be due to a shorter half-life of anti-SLAMF6 F(ab’)2,
which could prevent it from maintaining sustainable triggering
of SLAMF6 receptors during in vivo immune responses. Alterna-
tively, the suppressive effect of anti-SLAMF6 mAb on humoral
response might depend on the ability of anti-SLAMF6 Fc to bind
to other accessory cells and crosslink the SLAMF6 receptors on Tfh
cells and GC B cells. Such crosslinking is necessary for many sur-
face molecules to initiate signaling events. Clearly, further studies
are required to determine the contribution of other mechanisms
such as complement and non-NK cell-mediated cytotoxicity in
suppressing the activity of anti-SLAMF6 mAb. Compared to anti-
SLAMF6 mAb, anti-SLAMF1 mAb has a milder, yet consistent,
negative effect on antibody production, but anti-SLAMF5 mAb
does not show any impact on humoral response. It seems contra-
dictory to the functional redundancy we observed in Slamf[1+
5+ 6]−/− mice. In fact, SLAMF6 has been shown to initiate dom-
inant signaling in SAP−/− mice because ablation of the Slamf6
gene, but not the Slamf1 gene or Slamf5 gene, can rescue Tfh
cell differentiation and antibody responses in SAP−/− mice (27,
44). This indicates that SLAMF6 can complement deficiency of
either SLAMF1 or SLAMF5 to facilitate inhibitory signaling in the
absence of SAP. However, if Slamf1 and Slamf5 double mutations
can be introduced into SAP−/−mice, impaired humoral responses
may be partially restored. Similarly, the injection of mice with both
anti-SLAMF1 mAb and anti-SLAMF5 mAb may also cause some
reduction in antibody production.
By comparing T-dependent and T-independent antigen
responses in Slamf5−/−, Slamf[1+ 6]−/−, and Slamf[1+ 5+
6]−/−mice,we demonstrated for first time that SLAMF1,SLAMF5,
and SLAMF6 synergistically regulate humoral immune responses.
Genetic interruption of SLAMF1, SLAMF5, and SLAMF6 results in
enhanced antibody responses to T-dependent and T-independent
antigens. In complementary studies, the administration of anti-
SLAMF6 mAb further implicates SLAMF6 as a primary inhibitory
member of the SLAMF receptors in antibody responses. The stud-
ies suggest that the ligation of SLAMF receptors in SAP-negative
B cells (Figure 11) may preferentially recruit inhibitory signaling
molecules to immunological synapses and control B cell responses
during cognate interaction between T and B cells.
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